Roundtable Discussion: Aligning the Optimal Cellular Modality With the Right Indication to Maximize Patient Response: T Cells vs NK Cells vs Gamma-Delta T Cells
- Exploring how to leverage innate‑like recognition of stress‑induced antigens to defining indications where gamma delta T cells offer superior tumor surveillance compared with NK and T cells, particularly in heterogeneous or immune‑evasive tumors
- Identifying disease settings in which NK cells provide enhanced therapeutic benefit, including solid and liquid tumors through natural cytotoxicity and off‑the‑shelf compatibility
- Exploring combinatorial and multimodal strategies incorporating monoclonal antibodies, checkpoint inhibitors, cytokines, or other immunomodulators to amplify cellular immune responses, overcome tumor‑mediated immunosuppression, and achieve more durable tumor eradication